You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Mobile Three-Dimensional Screening for Cranial Malformations

    SBC: PEDIAMETRIX INC.            Topic: NIDCR

    ABSTRACTDelayed identification of infant head malformation is causing unnecessary medical complications and societal costs. A critical challenge in the early detection is the absence of tools available to pediatric offices to perform quantitative head shape assessment during well-child visits. Delays in diagnosis limit the opportunity for early, less invasive and effective treatment options. In th ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Simple and Accessible Microfluidic Platform for Single Molecule Sequence Profiling of Tumor-derived DNA within Liquid Biopsies

    SBC: HYPERMELT, LLC            Topic: 394

    Project Summary/ Abstract Over 600,000 people in the US will die from cancer this year. It is estimated that 25% of these deaths could have been prevented by detection in earlier stages. Implementation of minimally-invasive routine screening, such as pap smears for cervical cancer, has proven to be an effective approach for reducing cancer mortality. However, several challenges prevent successful ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Previvors Recharge: A Resilience Program for Cancer Previvors

    SBC: Pro-Change Behavior Systems, Inc.            Topic: 102

    It is estimated that approximately 5-10% of all diagnosed cancers are caused by Hereditary Cancer Syndromes (HCS) that are associated with germline mutations (inherited genetic mutations passed directly from a parent to a child that create a genetic predisposition to certain types of cancer). Recent epidemiologic models indicate that 1 in 279 people may be carriers of one of the most common HCS, a ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. A genetically modified Plasmodium falciparum sporozoite vaccine attenuated at the late-liver stage

    SBC: SANARIA INC.            Topic: NIAID

    ABSTRACT In 2020 malaria caused 241M clinical cases and 627,000 deaths, the greatest numbers of annual deaths since 2012. There were more deaths in Africa from malaria than from COVID-19. There is an urgent unmet medical need for a malaria vaccine that prevents infection and disease in individuals and can be deployed in mass vaccination programs for malaria elimination. The RTS,S malaria vaccine w ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Conditional male lethal Anopheles stephensi line for the efficient manufacture of malaria vaccines

    SBC: SANARIA INC.            Topic: NIAID

    Project Abstract In 2020 malaria cases (241M) and deaths (627,000) reached the highest since 2012 emphasizing the urgent need for new tools for prevention, control, and elimination of this disease. Sanaria’s Plasmodium falciparum (Pf) sporozoite (SPZ) Vaccine, composed of radiation attenuated PfSPZ administered by intravenous injection, assessed in 1740 subjects aged 5 months to 61 years in 6 co ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. High-throughput functional analysis and clinical relevance of all possible variants of a gene

    SBC: HELIGENICS, INC.            Topic: NHGRI

    Modern pharmaceuticals have greatly improved the quality of life for many patients suffering a variety of illnesses. Unfortunately, among the 17 most commonly prescribed drugs, only 6 are highly effective for most patients, 5 have a modest effect, and 6 show little clinical effect. Worse still, unwanted illness and death from treatment of patients with the incorrect drug or dosage causes over 275, ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. ErythroMer: Nanoscale BioSynthetic Red Cell Substitute

    SBC: KaloCyte Inc            Topic: NHLBI

    Research Summary/Abstract ErythroMer (EM) is a novel biosynthetic blood substitute developed to address the critically unmet need for emergency transfusion in situations where the use of banked red blood cells (RBCs) are either not available or undesirable. EM is a self-assembled lipid-oligomeric hybrid nanoparticle with a high per particle payload of hemoglobin (Hb) and the allosteric modifier, R ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Evaluation of a mobile app-based video Directly Observed Therapy (video DOT) intervention for medication adherence in pediatric heart transplant patients

    SBC: EMOCHA MOBILE HEALTH INC.            Topic: NHLBI

    Few interventions have proven to be successful in promoting medication adherence and impacting short- and long-term posttransplant outcomes in adolescent heart transplant (HT) recipients. Improving adherence is a persistent challenge with youth experiencing chronic health conditions, especially among adolescent transplant recipients. Adolescent organ transplant recipients experience unique challen ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Targeted ColQ gene therapy for Congenital Myasthenic Syndromes

    SBC: Amplo Biotechnology, Inc.            Topic: 106

    PROJECT SUMMARY Congenital Myasthenic Syndromes (CMS) are a group of clinically similar neuromuscular transmission disorders that differ in their underlying genetic mutation. While some phenotypical variation exists, CMS are commonly characterized by muscle weakness (myasthenia) that worsens with physical exertion. Defects in Collagen Q (ColQ), a multidomain functional protein of the Neuro Muscula ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. A Novel Synthetic Biology-Derived Microbiome Therapeutic to Treat Viral-Induced Acute Respiratory Distress Syndrome (ARDS)

    SBC: Rise Therapeutics, LLC            Topic: NIAID

    PROJECT SUMMARY Acute respiratory distress syndrome (ARDS) is a severe life-threatening complication that can be caused by viral infection. The disease is characterized by cytokine-driven hyperinflammation and leukocytes count changes. The innate immune response has been linked to ARDS immunopathogenesis. In this regard, neutrophils have been highlighted as essential effector cells in the developm ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government